| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Caffeic Acid Phenethyl Ester (CAPE) — CAPE is a propolis-derived phenolic ester and bioactive honeybee-hive constituent with pleiotropic anti-inflammatory and antineoplastic signaling effects. It is best classified as a natural polyphenolic small molecule and experimental adjunct candidate rather than an approved anticancer drug. Standard abbreviations include CAPE; common chemical naming includes caffeic acid phenethyl ester and phenethyl caffeate. CAPE is most strongly associated with poplar-type propolis chemistry, but it is also available as an ingredient in some dietary-supplement products. Current oncology relevance remains preclinical to early translational, with growing interest in chemosensitization and radiosensitization but no established cancer indication. Primary mechanisms (ranked):
Bioavailability / PK relevance: Oral translation is constrained by poor aqueous solubility, limited absorption, esterase-sensitive disposition, and substantial hydrolysis to caffeic acid in vivo. Rat PK work supports measurable exposure after oral dosing, but CAPE analogues with improved permeability outperform parent CAPE. Formulation strategies are therefore mechanistically relevant for systemic use. In-vitro vs systemic exposure relevance: Many direct anticancer studies use roughly 10–60 μM exposure, with some effects emerging near or above this range; those concentrations may exceed or stress the upper edge of practical systemic exposure with simple oral delivery. Tumor-directed claims should therefore be weighted more heavily when supported by in vivo xenograft, radiosensitization, or formulation-enabled data rather than cell culture alone. Clinical evidence status: Predominantly preclinical with in vitro, xenograft, and ex vivo support; small translational signals exist for radiosensitization/radioprotection concepts, but there is no established oncology trial program or approved cancer use for CAPE itself. CAPE — Cancer vs Normal Cell Pathway Map
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr |
| Source: TCGA |
| Type: Proapototic |
| TP53 is the most commonly mutated gene in human cancer. TP53 is a gene that encodes for the p53 tumor suppressor protein ; TP73 (Chr.1p36.33) and TP63 (Chr.3q28) genes that encode transcription factors p73 and p63, respectively, are TP53 homologous structures. p53 is a crucial tumor suppressor protein that plays a significant role in regulating the cell cycle, maintaining genomic stability, and preventing tumor formation. It is often referred to as the "guardian of the genome" due to its role in protecting cells from DNA damage and stress. TP53 gene, which encodes the p53 protein, is one of the most frequently mutated genes in human cancers. Overexpression of MDM2, an inhibitor of p53, can lead to decreased p53 activity even in the presence of wild-type p53. In some cancers, particularly those with mutant p53, there may be an overexpression of the p53 protein. Cancers with overexpression: Breast, lung, colorectal, overian, head and neck, Esophageal, bladder, pancreatic, and liver. |
| - | NA, | HCC, | NA |
| 5757- | CAPE, | Caffeic acid phenethyl ester (CAPE): pharmacodynamics and potential for therapeutic application |
| - | Review, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:395 Target#:236 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid